Declaration of interest
A Adalja owns stock in Merck and is on an advisory board for their anti-bacterial program. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
A reviewer on this manuscript has disclosed that they are a speaker for Abbvie, Gilead, Merck, and BioTest; an advisor for Abbvie, Gilead, and Merck; research support for Abbvie and Gilead. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.